Rissler K, Jost S, Mohadjer M, Mundinger F, Cramer H
Department of Neurology and Clinical Neurophysiology, University of Freiburg, F.R.G.
Neurosci Res. 1987 Jun;4(5):343-56. doi: 10.1016/0168-0102(87)90001-0.
The molecular size distribution of somatostatin-like immunoreactivity (SLI) in the cerebroventricular fluid of patients with Parkinson's disease, dystonic syndromes, multiple sclerosis, basal and midline tumors, epilepsy and pain syndromes was investigated by separation with a Sephadex G-50f column and subsequent radioimmunoassay of the eluate. Marked heterogeneity of SLI was observed in most of the pools investigated. The most conspicuous feature of the elution profiles was the preponderance of the peak coeluting with synthetic somatostatin-14, whereas the peaks comigrating with synthetic somatostatin-28 and attributable to precursor-like SLI represented only minor or trace amounts of total immunoreactivity. These findings are consistent with the greater biological activity of somatostatin-14 in the human central nervous system, whereas somatostatin-28 appears to represent the more active form in the pituitary and in the intestinal mucosa. Solely in the case of brain tumor patients, some differences could be seen, resulting in an approximately equal distribution of somatostatin-14 and somatostatin-28 in two pools of ventricular fluid and by the detection of a degradation product of somatostatin-14 in another one. These observations could be explained by a lowered barrier function as a consequence of increased intracranial pressure in case of brain tumors, which is well in accordance with a markedly elevated total protein content being a sign of a lowered barrier function.
采用葡聚糖凝胶G - 50f柱分离并对洗脱液进行放射免疫测定，研究了帕金森病、肌张力障碍综合征、多发性硬化症、基底及中线肿瘤、癫痫和疼痛综合征患者脑脊液中生长抑素样免疫反应性（SLI）的分子大小分布。在大多数研究样本中观察到SLI存在明显的异质性。洗脱图谱最显著的特征是与合成生长抑素 - 14共洗脱的峰占优势，而与合成生长抑素 - 28共迁移且归因于前体样SLI的峰仅占总免疫反应性的少量或痕量。这些发现与生长抑素 - 14在人类中枢神经系统中具有更高的生物活性一致，而生长抑素 - 28似乎是垂体和肠黏膜中更具活性的形式。仅在脑肿瘤患者中，可观察到一些差异，导致两个脑室液样本中生长抑素 - 14和生长抑素 - 28的分布大致相等，并且在另一个样本中检测到了生长抑素 - 14的降解产物。这些观察结果可以用脑肿瘤患者颅内压升高导致屏障功能降低来解释，这与总蛋白含量明显升高作为屏障功能降低的标志是相符的。
